Research programme: keratoconjunctivitis therapeutics - Adenovir Pharma

Drug Profile

Research programme: keratoconjunctivitis therapeutics - Adenovir Pharma

Alternative Names: APD-514; Epidemic keratoconjunctivitis therapeutics - Adenovir Pharma; Trisialic acid second generation drug - Adenovir Pharma

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adenovir Pharma; Umea University
  • Developer Adenovir Pharma
  • Class Eye disorder therapies; Sialic acids
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Infectious keratoconjunctivitis

Most Recent Events

  • 29 Jun 2015 Adenovir Pharma receives grant from Sweden's VINNOVA to develop ADP 514 for Infectious keratoconjunctivitis
  • 29 Jun 2015 Preclinical trials in Infectious keratoconjunctivitis in Sweden (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top